Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4101021 | 0.83 | NPBWR1 (0.50) | NPBWR1ALDH1A1GRIN1GRIN2BMCHR1 | |
| SCHEMBL10195530 | 0.81 | NPBWR1 (0.51) | NPBWR1ALDH1A1MCHR1 | |
| SCHEMBL14320356 | 0.76 | NPC1 (0.54) | NPBWR1ALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL13734641 | 0.74 | ADORA3 (0.58) | ALDH1A1HPGDL3MBTL1NPC1RAB9A | |
| SCHEMBL17025310 | 0.74 | NPBWR1 (0.49) | NPBWR1ALDH1A1GRIN1GRIN2BMCHR1 | |
| SCHEMBL30097268 | 0.73 | LMNA (0.46) | ALDH1A1HPGDL3MBTL1NPC1RAB9A | |
| SCHEMBL27409409 | 0.73 | LMNA (0.46) | ALDH1A1HPGDL3MBTL1NPC1RAB9A | |
| SCHEMBL1558301 | 0.72 | PIK3CD (0.53) | NPBWR1GRIN1GRIN2BCYP11B1CYP11B2 | |
| SCHEMBL4109782 | 0.72 | NPBWR1 (0.46) | NPBWR1ALDH1A1GRIN1GRIN2BSMN1; SMN2 | |
| SCHEMBL11936663 | 0.70 | MEN1 (0.44) | NPBWR1ALDH1A1HPGDGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | NPBWR1 2613/4885ALDH1A1 3674/4885HPGD 3245/4885 |
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | NPBWR1 2101/4885ALDH1A1 4333/4885HPGD 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.